Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma

Clinical and Experimental Allergy

Volumn 45, Issue 12, 2015, Pages 1779-1789

  Mastalerz, L ^a   Celejewska Wojcik N ^a   Wojcik K ^a   Gielicz, A ^a   Cmiel A ^b   Ignacak, M ^a   Oles K ^a   Szczeklik, A ^b   Sanak, M ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b AGH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Poland)

Author keywords

Asthma phenotype; Eicosanoids; Induced sputum; Latent class analysis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; ICOSANOID; LIPID; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN A2; PROSTAGLANDIN E2; PROSTAGLANDIN F; STEROID; AUTACOID;

ADULT; ARTICLE; ASTHMA; BLOOD ANALYSIS; CELL INFILTRATION; CHRONIC RHINOSINUSITIS; DISEASE SEVERITY; DRUG MEGADOSE; EOSINOPHILIA; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSENSITIVITY; INDUCED SPUTUM SUPERNATANT; INFLAMMATORY CELL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDIATOR RELEASE; MIDDLE AGED; NEUTROPHILIA; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; SUPERNATANT; CHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG FUNCTION TEST; METABOLISM; RISK FACTOR; SPUTUM;

ADULT; ASTHMA; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHENOTYPE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SPUTUM;

EID: 84947432262     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12654     Document Type: Article

References (45)

1. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-13.
2. Woodroof PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-95.
3. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
4. Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. J Allergy Clin Immunol 2014; 133:1557-63.
5. Siroux V, Basagaña X, Boudier A et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011; 38:310-7.
6. Bochenek G, Kuschill-Dziurda J, Szafraniec K, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol 2014; 133:98-103.
7. Lotvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-60.
8. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107-19.
9. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available from: http://www.ginasthma.org/. Accessed: June 11, 2014.
10. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005; 172:824-30.
11. Vachier I, Bonnans C, Chavis C et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005; 115:55-60.
12. 2 and cysteinyl leukotriene concentration: association with asthma severity and eosinophilic inflammation. Clin Exp Allergy 2010; 40:85-93.
13. Huynh ML, Malcolm KC, Kotaru C et al. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 2005; 172:972-9.
14. Cahill KN, Bensko JC, Boyce JA, Lidlaw TM. Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015; 135:245-52.
15. Sanak M, Gielicz A, Bochenek G, Kaszuba M, Niz˙ankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoids lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011; 127:1141-7.
16. 2 pathway upregulation: relation to asthma severity, control and Th2 inflammation. J Allergy Clin Immunol 2013; 131:1504-12.
17. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20:1-55.
18. Niz˙ankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8.
19. Chung KF, Wenzel SE, Brozek JL, Bush A, Kastro M, Sterk PJ. International ERS/ATS Guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-73.
20. Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A. Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1796-800.
21. Mastalerz L, Celejewska-Wójcik N, Wójcik K et al. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity. Allergy 2014; 69:1550-9.
22. Linzer DA, Lewis JB. poLCA: an R package for polytomous variable latent class analysis. J Stat Softw 2011; 42:1-29.
23. Dayton CM, Macready GB. Concomitant-variable latent-class models. J Am Stat Assoc 1998; 83:173-8.
24. Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical variables: one-step versus three-step estimators. Polit Anal 2004; 12:3-27.
25. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2008; 113:101-8.
26. Boyce JA. Eicosanoids in asthma, allergic inflammation, and host defence. Curr Mol Med 2008; 8:335-49.
27. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Disease 1991; 143:1025-9.
28. 4, and histamine in asthmatics. Am Rev Respir Disease 1992; 146:96-103.
29. Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91.
30. Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin intolerant asthma. Thorax 2008; 63:1076-82.
31. 2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111:743-9.
32. Deykin A, Lazarus SC, Fahy JV et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115:720-7.
33. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65:384-90.
34. Dente FL, Bacci E, Bartoli ML et al. Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma. Ann Allergy Asthma Immunol 2010; 104:464-70.
35. Brusselle GG, Maes T, Bracke KR. Eosinophils at the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19:977-9.
36. Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149:953-9.
37. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-9.
38. Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156:737-43.
39. Berry M, Hardagon B, Morgan A et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005; 25:986-91.
40. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011; 63:471-538.
41. Micheletto C, Visconti M, Tognella S, Facchini FM, Dal Negro RW. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs. AIA without polyps, mild topic asthma, and normal controls. Eur Ann Allergy. Clin Immunol 2006; 38:20-3.
42. 4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004; 113:277-83.
43. Lundgren JD, Shelhamer J, Kaliner MA. The role of eicosanoids in respiratory mucus hypersecretion. Ann Allergy 1985; 55:5-8.
44. Maier NK, Leppla SH, Moayeri M. The cyclopentenone prostaglandin 15-d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes. J Immunol 2015; 194:2776-85.
45. Zhu X, Walton RG, Tian L et al. Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily. Biol Pharm Bull 2005; 28:1603-7.